**Systemic Chemotherapy is a Promising Treatment Option for Patients with Colonic Stents: A Review**

Akihisa Matsuda\textsuperscript{1)}, Takeshi Yamada\textsuperscript{1)}, Satoshi Matsumoto\textsuperscript{2)}, Seiichi Shinji\textsuperscript{1)}, Ryo Ohta\textsuperscript{1)}, Hiromichi Sonoda\textsuperscript{1)}, Goro Takahashi\textsuperscript{1)}, Takuma Iwai\textsuperscript{1)}, Kohki Takeda\textsuperscript{1)}, Kumiko Sekiguchi\textsuperscript{3)} and Hiroshi Yoshida\textsuperscript{1)}

\textsuperscript{1)} Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan  
\textsuperscript{2)} Department of Surgery, Nippon Medical School Chiba Hokusoh Hospital, Kamagari, Inzai, Japan  
\textsuperscript{3)} Department of Surgery, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan

**Abstract**

Approximately 10\% of patients with colorectal cancer (CRC) develop malignant large bowel obstruction (MLBO) at diagnosis. Furthermore, for 35\% of patients with MLBO, curative primary tumor resection is unfeasible because of locally advanced disease and comorbidities. The practice of placing a self-expandable metallic stent (SEMS) has dramatically increased as an effective palliative treatment. Recent advances in systemic chemotherapy for metastatic CRC have significantly contributed to prolonging patients’ prognosis and expanding the indications. However, the safety and efficacy of systemic chemotherapy in patients with SEMS have not been established. This review outlines the current status of this relatively new therapeutic strategy and future perspectives. Some reports on this topic have demonstrated that 1) systemic chemotherapy and the addition of molecular targeted agents contribute to prolonged survival in patients with SEMS; 2) delayed SEMS-related complications are a major concern, and this requires strict patient monitoring; however, primary tumor control by chemotherapy might result in decreased complications, especially regarding re-obstruction; and 3) using bevacizumab could be a risk factor for SEMS-related perforation, which may be lethal. Although this relatively new approach for unresectable stage IV obstructive CRC requires a well-planned clinical trial, this therapy could be promising for patients who are unideal candidates for emergency surgery and require immediate systemic chemotherapy.

**Keywords**

obstructive colorectal cancer, malignant large bowel obstruction, self-expandable metallic stent, chemotherapy, bevacizumab

**Introduction**

Colorectal cancer (CRC), with an estimated worldwide mortality of 880,000 in 2018, is the leading cause of cancer-related death\cite{1}. In Japan, CRC was the most commonly diagnosed malignancy and the second leading cause of cancer-related death in 2015\cite{2}. Approximately 10\% of patients with CRC develop malignant large bowel obstruction (MLBO) at diagnosis\cite{3,4}. Among patients requiring emergency surgery for colorectal diseases, 85\% have MLBO\cite{3,4}. Furthermore, 35\% of patients with MLBO are unsuitable for curative primary tumor resection because of locally advanced disease and comorbidities\cite{5}.

Previously, invasive surgical approaches, including stoma creation, were the only option for managing MLBO, even in high-risk patients. The frequency of self-expandable metallic...
Semi-ent (SEMS) placement has dramatically increased as an effective treatment choice for palliation after its introduction in Japan. A recent meta-analysis reported significant benefits of palliative SEMS placement compared with emergency surgery in terms of morbidity, mortality, and equivalent prognosis[6]. Recent advances in systemic chemotherapy for metastatic CRC (mCRC) have significantly contributed to prolonging the prognosis and expanding the indications in the so-called “vulnerable patients.” Most patients with MLBO from mCRC who were candidates for SEMS placement were also outside the indications for systemic chemotherapy in the early period (i.e., purely palliative). However, SEMS placement is now closely associated with systemic chemotherapy, with the expanded indications. Although several reports evaluating the safety and efficacy of systemic chemotherapy in patients who underwent SEMS placement have emerged, the clinical usefulness of this approach is undetermined owing to sparse evidence. In this review article, we describe the current status of systemic chemotherapy for patients with SEMS and its future perspectives.

Optimal Procedures for SEMS Placement

The only indication for SEMS placement in CRC is the presence of both obstructive symptoms and radiological findings suspicious for MLBO. MLBO can occur before the first diagnosis and during treatment with palliative and systemic chemotherapy. A previous systematic review reported that the technical and clinical success rates were 96.2% (range: 66.2%-100%) and 92% (range: 46%-100%), respectively[7]. Notably, results from the pooled analysis of two Japanese multicenter prospective trials of SEMS placement as a bridge to surgery (BTS) were promising, and the study reported technical and clinical success rates of 98.1% and 93.8%, respectively[8,9]. Safe SEMS placement requires expertise and compliance with strict contraindications. The general contraindications for SEMS placement are perforation, penetration, shock state, prophylactic placement, massive invasion to other organs, lower rectal mass within 5 cm of the anal verge, and excessively long or complicated strictures. Obtaining endoscopic biopsies before or during SEMS placement is recommended to confirm malignancy and perform genetic testing for future molecular targeted therapy; however, biopsies are often unfeasible in the emergency setting. Several studies have evaluated the learning curve of successful SEMS placement and have shown that 20 procedures are required to increase technical success and decrease the number of stents per procedure[10,11]. Small et al.[12] reported a higher acute perforation rate in procedures performed by endoscopists inexperienced in pancreaticobiliary endoscopy. A post-hoc analysis of a multicenter study in Japan identified factors related to the technical difficulty in SEMS placement using a cut-off procedure time of 45 min. The authors showed that complete obstruction requiring emergency intestinal decompression, right-sided colon, stenosis length over 5 cm, peritoneal carcinomatosis, and multiple SEMS placement were associated with technical difficulty[13]. Detailed information regarding safe SEMS placement is provided in the mini-guidelines established by the Colonic Stent Safe Procedure Research Group (http://colonic-stent.com).

Pros and Cons of Primary Tumor Resection in Stage IV CRC

The primary goal of treatment for unresectable stage IV CRC is not to achieve a cure but to prolong survival and maintain patients’ quality of life (QOL); hence, the main treatment is systemic chemotherapy. Historically, many surgeons have advocated primary tumor resection, mainly to avoid potential primary tumor-related complications, such as bleeding, perforation, or obstruction, and because surgery allows precise tumor staging (e.g., peritoneal metastasis)[14]. Several basic studies have suggested that in the presence of the primary tumor, the liver parenchyma adjacent to metastases provided fertile angiogenic tissue for metastatic tumor growth and may explain the association of primary tumor resection with improved survival[15]. The benefits of primary tumor resection have also been discussed; however, this clinical question has not reached a consensus. Patients with obvious symptoms related to the primary tumor, such as bleeding and obstruction, undergo primary tumor resection. The 2019 Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines[16] state that if symptoms exist as a result of the primary tumor that is difficult to control using other therapies, and resection is not significantly invasive, primary tumor resection and early systemic chemotherapy are recommended. However, patients with unresectable stage IV CRC requiring emergency admission owing to symptoms caused by the primary tumor account for only up to 4% of patients[17]. The oncological advantage of primary tumor resection without symptoms is undetermined. The Japanese guidelines state that the efficacy of resecting an asymptomatic primary tumor has not been established[16]. Recent advances in systemic chemotherapy for mCRC have dramatically prolonged patients’ survival and are associated with preferable oncological responses not only at the metastatic site but also in the primary tumor. These developments may have contributed to the paradigm shift from primary tumor resection first to introducing systemic chemotherapy first in daily clinical practice. The annual rate of palliative primary tumor resection has decreased from 74.5% in 1998 to 57.4% in 2010 in the United States[18]. Most studies have demonstrated that primary tumor resection improved oncological outcomes more than in patients without resection; however, these studies were retro-
spective, which involves considerable selection bias caused by choosing patients able to tolerate primary tumor resection[19-21]. In Japan, two large retrospective studies by Shida et al.[22] (n = 770) and Ishihara et al.[23] (n = 1982) using propensity score matching to minimize selection bias demonstrated that primary tumor resection was associated with better overall survival (OS) than no resection (hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.48-0.70, \( p < 0.01; \) HR 0.41, 95% CI 0.33-0.53, \( p < 0.0001 \), respectively). However, the study period for patient enrollment for these studies occurred in an earlier era of systemic chemotherapy. Subsequently, Shida et al.[24] identified patients who received systemic chemotherapy consisting of at least one molecular targeted agent, such as bevacizumab, cetuximab, or panitumumab, (n = 208) and used propensity score matching to compare patients with and without primary tumor resection. This more recent study, conducted in the current era of chemotherapy, showed that primary tumor resection was only marginally influential and did not significantly improve OS compared with no primary tumor resection (HR 0.76, 95% CI 0.51-1.15, \( p = 0.197 \)). To clarify the oncological benefit of primary tumor resection in patients with asymptomatic stage IV CRC, several randomized controlled trials (RCTs) have been conducted. Among these, the results of the JCOG1007 trial (IPACS study) (n = 160) were presented at the ASCO-GI 2020[25]. The trial was terminated early based on its futility and demonstrated that primary tumor resection followed by chemotherapy had no superiority regarding OS compared with chemotherapy without primary tumor resection (HR 1.10, 95% CI 0.76-1.59, \( p = 0.69 \)).

When considering resecting a symptomatic primary tumor, surgical risks should be considered. Although the JSCCR guidelines[16] recommend primary tumor resection if the surgery is not significantly invasive for the patient, estimating whether the surgery will be overly invasive is practically difficult. Patients with unresectable stage IV obstructive CRC have poor nutritional status, are immunosuppressed, and suffer from chronic inflammation, which can cause increased postoperative morbidity and mortality[26,27]. A study by Stelzer et al.[28] reported a surprisingly high mortality of 11.7% in patients with unresectable stage IV obstructive CRC who underwent primary tumor resection. The study demonstrated that patients requiring emergency surgery to address primary tumor symptoms had significantly higher mortality than patients undergoing elective surgery (27.8% vs. 7.3%, respectively). A review by de Mestier et al.[29] reported high morbidity and mortality (13%-48% and 2%-11.7%, respectively) after asymptomatic primary tumor resection. Notably, the JCOG1007 trial reported a mortality of 4% and morbidity of 38%, which are considerably higher than those of curative nonmetastatic CRC surgeries[30]. Since initial primary tumor resection can lead to significant delays in introducing effective systemic chemotherapy, and that postoperative complications and surgical stress induce exaggerated inflammatory host responses and decrease tumor immunity, which can result in rapid tumor progression (“surgical oncotaxis”)[31-33], primary tumor resection should be performed within strict indications.

**Indications for Systemic Chemotherapy in Patients with SEMS**

Although unresectable stage IV patients with an obstructive primary tumor can achieve maximal benefits from SEMS placement by avoiding high-risk emergency surgery and permanent stoma creation, which is associated with stoma-related complications and poor health-related QOL[34], the efficacy and safety of systemic chemotherapy after SEMS placement have not been established. Accordingly, primary tumor resection and/or stoma creation should be performed in patients who are candidates for systemic chemotherapy. However, patients with 1) high surgical risk, 2) abundant tumor burden or rapid progression requiring immediate chemotherapy introduction, and 3) declining stoma creation could be candidates for chemotherapy after SEMS placement. Initial SEMS placement permits earlier initiation of chemotherapy, which is superior to delayed chemotherapy administration in terms of QOL and OS[35]. Additionally, the benefits of sequential SEMS placement for subsequent obstructions after prior systemic chemotherapy are assumed. Approximately 20% of patients with prior systemic chemotherapy develop primary tumor obstruction[20,36]. A high mortality rate (3.7%-12.5%) and serious morbidity (7.4%-11.8%) have been reported with palliative surgery for these patients[37-39] suggesting decreased immunity and poor general condition owing to chemotherapy continuation and disease progression. In these patients, the benefits of minimally invasive SEMS placement over surgery would be enhanced.

**Previous Reports of Systemic Chemotherapy in Patients with SEMS**

Although studies investigating the efficacy of systemic chemotherapy in patients with SEMS are limited to small sample sizes, several studies have demonstrated significantly better survival with systemic chemotherapy in patients with SEMS compared with best supportive care (BSC)[40,41]. However, systemic chemotherapy may increase the risk of SEMS-related complications, such as migration resulting from tumor response, re-obstruction due to in- and outgrowth of the tumor, and perforation, which could be potentially critical[42-44]. Findings in published reports (including patients with and without chemotherapy) have shown procedure- and SEMS-related complications in 5%-23% of patients, with an average rate of SEMS-related perforation in
5% of patients[12,45-47]. Hence, the decision to proceed with SEMS placement must consider the risks of long-term SEMS-related complications weighed against the lower short-term mortality and an earlier start to chemotherapy. Moreover, prolonged survival derived from systemic chemotherapy in patients with SEMS might result in more patients being exposed to the risk of delayed SEMS-related complications[48,49].

Previous representative studies investigating the efficacy and safety of systemic chemotherapy in patients with SEMS are summarized in Table 1[41,50-53]. A multicenter retrospective study by Ceze et al.[50] reported that the response rate and disease control rate in patients who underwent first-line chemotherapy without molecular targeted drugs (n = 38) were 38% and 62%, respectively, and the median progression-free survival (PFS) and OS were 5 months and 18 months, respectively. These oncological outcomes were similar to previous clinical trials using similar regimens (i.e., oxaliplatin- or irinotecan-based regimens without molecular targeted drugs), and the toxicity was generally acceptable at 32% grade 3-4 toxicity among all patients. Although the relatively high perforation rate of 8%, which occurred after 2-15 months of placement, was not negligible, the authors concluded that chemotherapy in patients with SEMS appeared to be a valid option.

Fuccio et al.[51] reported a detailed analysis of 91 patients who underwent palliative SEMS placement, 82 of whom received chemotherapy. The distribution of wild-type and mutant KRAS was 48.4% and 51.6%, respectively, which was similar previously reported rates for patients without obstruction. SEMS-related complications constituted re-obstruction in 12.1%, perforation in 8.8%, and migration in 2.2% of patients. The clinical success rates of decompression at 12 and 24 months were 70.7% and 42.2%, respectively. Analyzing only patients who died, revealed clinical success in 78% of the patients, which implied that SEMS had sufficient palliative value until their death in patients treated with systemic chemotherapy. No significant differences in clinical success were observed between chemotherapy-treated patients with and without molecular targeted drugs, and between bevacizumab and cetuximab. Chemotherapy did not influence the risk of SEMS-related complications (Odds ratio (OR) 0.56, 95% CI 0.14-2.9, \( p = 0.446 \)), and no evidence was found that patients treated with chemotherapy and cetuximab were more likely to experience SEMS-related complications than patients treated with chemotherapy alone or with BSC (OR 1.2, 95% CI 0.2-5.9, \( p = 0.856 \)). In the OS analysis, patients receiving molecular targeted drugs had significantly longer OS than those receiving only chemotherapy (384 days vs. 240 days, respectively) (risk ratio (RR) 0.5, 95% CI 0.3-0.9, \( p = 0.02 \)). The study concluded that chemotherapy and using molecular targeted drugs did not influence SEMS-related complications.

Pacheco-Barcia et al.[41] reported a retrospective case series of 78 patients who underwent palliative SEMS placement. Patients were divided into three groups: BSC (n = 31), chemotherapy alone (n = 31), and chemotherapy with bevacizumab (n = 16). The study showed that chemotherapy significantly improved OS compared with BSC (27 months vs. 11 months, respectively; \( p < 0.01 \)) and that bevacizumab showed a significant OS benefit compared with chemotherapy alone (43 months vs. 20 months, respectively; \( p = 0.02 \)). The overall major SEMS-related complication rate (35%) and perforation rate (5%) equaled those in previous studies, and receiving chemotherapy was an independent risk factor for developing SEMS-related complications (OR 1.84, 95% CI 1.29-6.22, \( p = 0.007 \)), but not for perforations (OR 1.82, 95% CI 0.33-10.07, \( p = 0.39 \)). However, bevacizumab treatment showed a nonsignificant trend toward increased perforation rates compared with chemotherapy alone (12.5% vs. 8%, respectively; \( p = 0.47 \)).

Theoretically, prolonged survival with systemic chemotherapy may increase the risk of SEMS-related complications because chemotherapy prolongs the duration of SEMS implantation in vivo. Abbot et al.[54] reviewed 145 patients undergoing palliative SEMS placement and found that 26.7% experienced delayed SEMS-related complications. Systemic chemotherapy in patients with SEMS was a significant risk factor for delayed complications (OR 5.52, 95% CI 1.76-17.3, \( p = 0.003 \)) and endoscopic re-intervention (OR 4.30, 95% CI 1.31-14.2, \( p = 0.018 \)) on multivariate analysis. In contrast, some have the opinion that systemic chemotherapy can prevent SEMS-related complications. Di Mitri et al.[40] showed in a retrospective study of 204 patients who underwent SEMS placement that palliative SEMS placement itself was associated with an increased risk of tumor ingrowth (OR 7.7, 95% CI 1.25-59.7, \( p = 0.005 \)), but chemotherapy significantly decreased the risk of tumor ingrowth (OR 0.26, 95% CI 0.08-0.83, \( p = 0.016 \)). Yoon et al.[44] also demonstrated that chemotherapy was a significant negative risk factor for long-term SEMS-related clinical failure (OR 0.52, 95% CI 0.31-0.88, \( p = 0.015 \)) in a retrospective cohort study of 412 patients with SEMS. These positive effects of chemotherapy against SEMS-related complications, especially for re-obstruction by tumor growth, may have been caused by the effects of tumor shrinkage induced by chemotherapy. However, Fernández-Esparrach et al.[55] strongly suggested that palliative treatment for obstructive primary tumors other than with SEMS placement should be considered in incurable patients eligible for chemotherapy and with a long life expectancy, based on the high rate of long-term SEMS-related clinical failure (51%, 17/33) and subsequent mortality (15%, 8/33).

The previously reported survival of chemotherapy-treated patients after SEMS placement (Table 1) appears to be inferior to that obtained in the current era of aggressive cyto-
Table 1. Previous Representative Studies of Systemic Chemotherapy during SEMS Placement.

| Author      | Country | Year        | Institution       | Study Design  | Study period | Sample size (%) | Group  | Age (range) | Gender (male: %) | Tumor location (left: %) | Interval from SEMS to chemo (days: range) | Regimen               | Patency (days: med) (range) | Overall (%) | Migration (%) | Perforation (%) | Re-obstruction (%) | PFS (med) | OS (med) |
|-------------|---------|-------------|-------------------|---------------|--------------|----------------|--------|-------------|-------------------|---------------------------------|-------------------------------|-------------------------|----------------------------|----------------|----------------|-------------------|-------------------------|-----------|---------|
| Karoui      | France  | 2007       | Single RS        | 2000-2005     | 31           | All (72)       | 15 (48.4) | 28 (90.3)   | 14 (3-60)         |                                 | 5 (16)                         | 2 (6.5)                 | 3 (10)                  | 13.7 m                  |
| Lee         | Korea   | 2012       | Single RS        | 2000-2008     | 36           | Chemo (60.3)   | 22 (61.1) | 32 (88.9)   | Overall           | Oxaliplatin (n = 20)          | 115 (25.1)                  | 9 (5.6)                 | 2 (1.8)                 | 5 (13.9)               | 7.6 m                  |
| Fuccio      | Italy   | 2014       | Multi RS         | 2007-2011     | 91           | All (64.6)     | 61 (67)   | 84 (92.3)   | Overall           | Irinotecan (n = 16)          | 90 (4-720)*                  | 21 (23.1)               | 8 (8.8)                 | 11 (12.1)              | 330 days               | 240 days   |
| Ceze        | France  | 2016       | Multi RS         | 2001-2007     | 38           | Chemo (65)     | 18 (47)   | 32 (84)     | Overall           | FOLFOX (n = 24)              | 146 (26-1062)               | 10 (26)                 | 2 (5.3)                 | 3 (7.9)                 | 5 (13)                 | 5m        | 18m     |
| Pacheco      | Spain   | 2019       | Multi RS         | 2012-2017     | 78           | All (76)      | 29 (37)   | 73 (94)     | Overall           | FOLFIRI (n = 5)              | 27 (35)                     | 2 (2.5)                 | 7 (9)                   | 14 (18)                | 11 m                   | 20 m      |
| Bacia       |         |             |                   |               |              | BSC (39.5)    | 13 (16)   | 29 (94)     | 8 (26)            |                                 | 13 (3)                       | 1 (3)                   | 7 (16)                  |                         | 43 m                   |
|             |         |             |                   |               |              | Chemo (39.5)  | 13 (16)   | 29 (94)     | 13 (3)            |                                 | (42)                        | 3 (9.7)                 | 7 (22.5)                |                         |                       |
|             |         |             |                   |               |              | alone (34)    | 13 (34)   | 29 (94)     | 13 (3)            |                                 | (37.5)                      | 0 (0)                   | 12.5 (12.5)             |                         |                       |

RS: retrospective study, chemo: chemotherapy, BSC: best supportive care, SEMS: self-expandable metallic stent, PFS: progression-free survival, OS: overall survival, BV: bevacizumab, Cet: cetuximab, m: month
toxic and molecular targeted therapy, which is approaching a median survival of 30 months[56-58]. Along with SEMS-related complications, long-term survival should be evaluated in future studies with large sample sizes.

**Antiangiogenic Agents in Chemotherapy after SEMS Placement**

Bevacizumab is a recombinant, humanized monoclonal antibody that binds to and blocks the activity of vascular endothelial growth factor-A, a family of a member of vascular endothelial growth factor receptor-activating ligands. Gastrointestinal perforation is a well-documented side effect of bevacizumab and occurs at a rate of 1%-2%[59]. Bevacizumab administration for patients who underwent SEMS placement increases the risk of perforation[12,60]. Retrospective studies reported an approximately threefold higher rate of perforation in patients who underwent SEMS placement and subsequently received bevacizumab than in those who were not treated with bevacizumab after SEMS placement[12,60]. Bevacizumab-induced perforation during SEMS placement is caused by the radial force of the SEMS on the colonic cancer tissue, which is weakened by the antiangiogenic effect of the drug[61]. In a meta-analysis by Halsema et al.[62], perforation rates in patients treated with chemotherapy with bevacizumab, chemotherapy alone, and BSC were 12.5% (95% CI 6.4-22.8), 7.0% (95% CI 4.8-10.0), and 9.0% (95% CI 7.2-11.1), respectively. The study concluded that bevacizumab-based therapy was a risk factor for perforation, whereas chemotherapy alone was not associated with an increased risk of perforation. In contrast, a recent relatively large retrospective study by Park et al.[63] reported that perforation rates in patients with bevacizumab (n = 96) and without bevacizumab (n = 257) were equivalent at 7.3% and 7.0%, respectively (p = 0.93). The study also showed that chemotherapy did not increase the perforation risk after SEMS placement and that chemotherapy significantly decreased the mortality risk (HR 0.46, 95% CI 0.32-0.68, p < 0.001)[63]. Regarding the perforation risk of SEMS placement in patients with previous bevacizumab use, Bong et al.[64] demonstrated that SEMS was a significant risk factor for complications requiring surgery in patients already receiving bevacizumab (HR 5.69, 95% CI 2.37-13.64, p = 0.001). Halsema et al.[62] also stated in their meta-analysis that SEMS placement should be avoided, if possible, in patients with previous bevacizumab use.

While most cases of SEMS-related complications, such as migration and re-obstruction, can be managed by endoscopic re-intervention with removal and re-stenting, respectively, perforation is difficult to manage with conservative treatment and requires emergency surgical management. Considering that perforation in patients after SEMS placement is associated with higher mortality compared with other complications, perforation cannot be treated uniformly as a complication and should be managed with exceptional caution. Lee et al.[65] analyzed 21 perforated cases after SEMS placement and showed that 14 cases (66.7%) required emergency surgeries, and 5 cases (23.8%) died within 30 days.

**Guideline Statements for Chemotherapy after SEMS Placement**

The 2019 JSCCR guidelines questioned SEMS placement in patients experiencing obstructive CRC for the first time. The guidelines do not recommend systemic chemotherapy because “Stent treatment is not recommended for patients who are indicated for systemic therapy (Recommendation 2/ Evidence level B)”[16]. The guidelines state that this recommendation is based on the possibility of chemotherapy causing tumor shrinkage and tissue necrosis, which can lead to perforation and penetration to surrounding organs.

The European Society of Gastrointestinal Endoscopy (ESGE) guidelines for SEMS for obstructive colonic and extracolonic cancer published in 2014[66] stated that “Patients who have undergone palliative stenting can be safely treated with chemotherapy without antiangiogenic agents” and “given the high risk of perforation, it is not recommended to use SEMS as palliative decompression if a patient is being treated or considered for treatment with antiangiogenic therapy” (“strong recommendation, low quality evidence” in both statements). Notably, this statement conflicts with the Japanese guidelines, which do not recommend SEMS placement, regardless of chemotherapy with or without antiangiogenic agents. The updated version of the 2020 ESGE guidelines[67] essentially followed the previous version but modified the recommendation regarding the association between SEMS and antiangiogenic agent use. The updated guidelines suggest that antiangiogenic therapy can be considered in patients following colonic stenting and do not suggest colonic stenting while patients are receiving antiangiogenic therapy (“weak recommendation, low quality evidence” in both statements)[67]. The World Society of Emergency Surgery (WSES) guidelines on colon and rectal cancer emergencies, which was updated in 2017,[68] state that “alternative treatments to SEMS should be considered in patients eligible to receive a bevacizumab-based therapy” and “Involvement of the oncologist in the decision is strongly recommended” (level of evidence 3 and grade of recommendation B) (Table 2).

Although no data are currently available, the JSCCR and ESGE guidelines[16,66] advise against the use of other agents that inhibit angiogenesis as well as bevacizumab, such as regorafenib, aflibercept, and ramucirumab, because of the speculated high risk of perforation.
and safe introduction of systemic chemotherapy in a mini-
IV obstructive CRC, it is important to facilitate the quick
placement. Systemic chemotherapy with anti-epidermal growth
mally invasive manner that does not worsen treatment out-
comes and that maintains patients’ QOL. Among the choices
for intestinal decompression, SEMS placement is a promis-
ing option that satisfies these goals. However, SEMS place-
ment followed by systemic chemotherapy involves consid-
erable disadvantages, namely, a concern for delayed SEMS-
related complications, which could be critical, and the un-
availability of bevacizumab (and other antiangiogenic
agents). Notably, molecular targeted drugs are not an option
for patients with the RAS mutation. However, a previous
pivotal study evaluating the additional effect of bevacizumab
to oxaliplatin-based first-line chemotherapy improved both
PFS and OS only for 1.4 months, and the statistically sig-
ificant difference was observed only in PFS, but not in OS[69]. Additionally, the disadvantage of bevacizumab un-
availability might be limited because most patients with ob-
structive cancers who are candidates for SEMS placement
have left-sided CRC, which is associated with less survival
benefit with bevacizumab administration than right-sided
CRC[70]. Taken together, the considerable above-mentioned
benefits of SEMS placement followed by immediate chemo-
therapy without bevacizumab might outweigh the benefits of
bevacizumab availability after invasive surgical intestinal de-
compression, including stoma creation.

Figure 1 shows our treatment strategy for patients with un-
sectable stage IV obstructive CRC after SEMS place-
ment. Systemic chemotherapy with anti-epidermal growth

![Figure 1](image-url)

**Figure 1.** Therapeutic strategy for systemic chemotherapy after SEMS placement.

**CRC**, colorectal cancer; **TDT**, transanal decompression tube; **SEMS**, self-expandable metallic stent.

## Our Therapeutic Strategy for Systemic Chemotherapy after SEMS Placement and Future Perspectives

For treating non-curable patients with unresectable stage IV obstructive CRC, it is important to facilitate the quick and safe introduction of systemic chemotherapy in a mini-

### Table 2. Guideline Statements for Chemotherapy during SEMS Placement.

| Guideline | Source of publication | Recommendation and comments | Recommendation Grade/Evidence Level |
|-----------|-----------------------|----------------------------|-------------------------------------|
| JSCCR guidelines 2019 for the treatment of colorectal cancer | The Japanese Society for Cancer of the Colon and Rectum (JSCCR) | (Recomendation)  
- Stent treatment is not recommended for patients who are indicated for systemic therapy  
(Comments)  
- Indication should be judged carefully due to the perforation risk by tumor shrinkage and necrosis.  
- Refrain from bevacizumab use, which can increase the perforation risk.  
- Other antiangiogenic agents (regorafenib, ramucirumab, aflibercept) are supposed to have similar perforation risk. | 2/B |
| Self-expandable metal stents for colonic and extracolonic cancer: ESGE Guideline - Update 2020 | The European Society of Gastrointestinal Endoscopy (ESGE) | (Recomendation)  
- ESGE recommends chemotherapy as a safe treatment in patients who have undergone palliative colonic stenting.  
- ESGE suggests antiangiogenic therapy (e.g., bevacizumab) can be considered in patients following colonic stenting.  
- ESGE does not suggest colonic stenting while patients are receiving antiangiogenic therapy, such as bevacizumab. | Strong/low quality |
| 2017 WSES guidelines on colon and rectal cancer emergencies | The World Society of Emergency Surgery (WSES) | (Recomendation)  
- Alternative treatments to SEMS should be considered in patients eligible for a bevacizumab-based therapy, and involvement of the oncologist in the decision is strongly recommend- ed. | B/3 |
factor receptor (EGFR) antibody and chemotherapy without molecular targeted drugs is introduced as soon as possible after SEMS placement in patients with wild-type RAS and RAS mutation, respectively. Early tumor shrinkage (ETS) 6-8 weeks after chemotherapy introduction, which is a reliable surrogate marker for better survival[71], is evaluated, and primary tumor resection is planned for patients with ETS. Primary tumor resection in patients with ETS at this time point prevents delayed SEMS-related complications and is associated with longer survival, with the additional effect of bevacizumab administration in patients with the RAS mutation. In contrast, patients without ETS are likely to have shorter survival, implying that the benefit of primary tumor resection (i.e., prevention of delayed SEMS-related complications) is relatively limited. Therefore, the continuation of chemotherapy (and a shift to subsequent treatment lines) without primary tumor resection is recommended, with an emphasis on maintaining patients’ QOL.

Patients requiring emergency intestinal decompression at the initial visit have a disadvantage in that the physician cannot refer to the patient’s RAS status before SEMS placement. In patients who are not candidates for emergency surgery, including colostomy, and who require more intensive chemotherapy, temporal intestinal decompression using a transanal decompression tube could be considered until RAS status confirmation. SEMS placement followed by chemotherapy with anti-EGFR antibody in patients with wild-type RAS and elective primary tumor resection followed by chemotherapy with bevacizumab in patients with the RAS mutation might also be effective options.

In Japan, liquid biopsy assessing RAS status was covered by the public health insurance system in August 2020. Considering that obtaining biopsy specimens for patients who require emergency SEMS placement is technically difficult, liquid biopsy could be a useful tool for the optimization of anti-EGFR antibody administration and monitoring drug resistance[72].

Conclusions

This review outlined the current status of systemic chemotherapy in patients with SEMS with unresectable stage IV obstructive CRC. Owing to the limited survival benefit and considerable surgical risks, patients with unresectable stage IV obstructive CRC might not be recommended to undergo primary tumor resection. Under such circumstances, it is speculated that the physician will encounter the opportunity to consider systemic chemotherapy after SEMS placement more frequently; however, the related evidence is extremely limited, and conclusions are undetermined. Safe and effective systemic chemotherapy for patients with SEMS is based on compliance with well-considered indications, sufficient informed consent, experienced endoscopists, and strict monitoring for related complications. Although this relatively new approach for unresectable stage IV obstructive CRC requires a well-planned clinical trial, this could be a promising therapeutic option for patients who are unideal candidates for emergency surgery and who require immediate introduction of systemic chemotherapy.

Acknowledgements

We thank Jane Charbonneau, DVM, from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Conflicts of Interest

There are no conflicts of interest.

Disclaimer

Takeshi Yamada is one of the Associate Editors of Journal of the Anus, Rectum and Colon and on the journal’s Editorial Board. He was not involved in the editorial evaluation or decision to accept this article for publication at all.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394-424.
2. Center for Cancer Control and Information Services, National Cancer Center. Cancer Statistics in Japan, 2017 [Internet]. [place unknown] 2018 [cited 2019 Feb 20]. Available from: https://ganjoho.jp/en/professional/statistics/brochure/2017_en.html.
3. Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Brit J Surg. 1994 Sep; 81(9): 1270-6.
4. Yeo HL, Lee SW. Colorectal emergencies: review and controversies in the management of large bowel obstruction. J Gastrointestinal Surg. 2013 Nov; 17(11): 2007-12.
5. Carraro PG, Segala M, Cesana BM, et al. Obstructing colonic cancer: failure and survival patterns over a ten-year follow-up after one-stage curative surgery. Dis Colon Rectum. 2001 Feb; 44(2): 243-50.
6. Takahashi H, Okabayashi K, Tsuruta M, et al. Self-expanding metallic stents versus surgical intervention as palliative therapy for obstructive colorectal cancer: a meta-analysis. World J Surg. 2015 Aug; 39(8): 2037-44.
7. Watt AM, Faragher IG, Griffin TT, et al. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. Ann Surg. 2007 Jul; 246(1): 24-30.
8. Saito S, Yoshida S, Isayama H, et al. A prospective multicenter study on self-expandable metallic stents as a bridge to surgery for malignant colorectal obstruction in Japan: efficacy and safety in 312 patients. Surgi Endosc. 2016 Sep; 30(9): 3976-86.
9. Matsuzawa T, Ishida H, Yoshida S, et al. A Japanese prospective multicenter study of self-expandable metal stent placement for malignant colorectal obstruction: short-term safety and efficacy within 7 days of stent procedure in 513 cases. Gastroint Endosc. 2015 Oct; 82(4): 697-707 e1.
10. Lee JH, Yoon JY, Park SJ, et al. The learning curve for colorectal stent insertion for the treatment of malignant colorectal obstruct-
tion. Gut Liver. 2012 Jul; 6(3): 328-33.
11. Williams D, Law R, Pullyblank AM. Colorectal stenting in malignant large bowel obstruction: the learning curve. Int J Surg Oncol. 2011.
12. Small AJ, Coelho-Prabhhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colorectal obstruction: long-term outcomes and complication factors. Gastrointest Endosc. 2010 Mar; 71(3): 560-72.
13. Kuwai T, Yamaguchi T, Imagawa H, et al. Factors related to difficult self-expandable metallic stent placement for malignant colorectal obstruction: A post-hoc analysis of a multicenter study across Japan. Dig Endosc. 2019 Jan; 31(1): 51-8.
14. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 2005 Aug; 12(8): 637-45.
15. van der Wal GE, Gouw AS, Kamps JA, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg. 2012 Jan; 255(1): 86-94.
16. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020 Jan; 25(1): 1-42.
17. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000 May; 135(5): 530-4; discussion 4-5.
18. Hu CY, Bailey CE, You YN, et al. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015 Mar; 150(3): 245-51.
19. Gresham G, Renouf DJ, Chan M, et al. Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients. Ann Surg Oncol. 2014 Nov; 21(12): 3917-23.
20. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010 Apr; 34 (4): 797-807.
21. Tarantino I, Warschow K, Warni M, et al. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis. Ann Surg. 2015 Jul; 262(1): 112-20.
22. Shida D, Hamaguchi T, Ochiai H, et al. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: using a propensity score analysis. Ann Surg Oncol. 2016 Oct; 23(11): 3602-8.
23. Ishihara S, Hayama T, Yamada H, et al. Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol. 2014 Sep; 21(9): 2949-55.
24. Shida D, Boku N, Tanabe T, et al. Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy. J Gastrointest Surg. 2019 Nov; 23(11): 2144-50.
25. Kanemitsu Y, Shitara K, Mizusawa J, et al. A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). J Clin Oncol. 2020 Feb; 38(4): 7.
26. Akagi J, Baba H. Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. Oncology Rep. 2019 Jan; 41(1): 301-11.
27. Matsuda A, Yamada M, Matsumoto S, et al. Blood galectin-3 levels predict postoperative complications after colorectal cancer surgery. J Nippon Med Sch. 2019 Jun; 86(3): 142-8.
28. Stelzer N, Hellmich G, Koch R, et al. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005 Mar; 89(4): 211-7.
29. de Mestier L, Manseau G, Neuzillet C, et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol. 2014 Jun; 6(6): 156-69.
30. Yamamoto S, Inomata M, Katayama H, et al. Short-term outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg. 2014 Jul; 260(1): 23-30.
31. Matsuda A, Jacob A, Wu R, et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. J Nippon Med Sch. 2012 Mar; 79(1): 4-18.
32. Matsumoto Y, Tsuchimoto H, Ono S, et al. Abdominal infection suppresses the number and activity of intrahepatic natural killer cells and promotes tumor growth in a murine liver metastasis model. Ann Surg Oncol. 2016 Feb; 23(2): 257-65.
33. Mimezami A, Mimezami R, Chandrakumar N, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011 May; 253(5): 890-9.
34. Vandervoort J, Tham TC. Colonic stents for malignant obstruction--not a bridge too far? Gastrointest Endosc. 2006 Dec; 64(6): 921-4.
35. Karoui M, Sopran I, Charachon A, et al. Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010 Jan; 36(1): 58-64.
36. Scheer MG, Sloots CE, van der Wilt GI, et al. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008 Nov; 19(11): 1829-35.
37. Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009 Feb; 35(2): 164-7.
38. Kim MS, Chung M, Ahn JB, et al. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. J Surg Oncol. 2014 Aug; 110(2): 214-21.
39. Poultides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009 Jul; 27(20): 3379-84.
40. Di Mitri R, Moccio M, Traina M, et al. Self-expandable metal stents for malignant colorectal obstruction: data from a retrospective regional SIED-AIGO study. Dig Liver Dis. 2014 Mar; 46(3): 279-82.
41. Pacheco-Barcia V, Mondejar R, Martinez-Saez O, et al. Safety and oncological outcomes of bevacizumab therapy in patients with advanced colorectal cancer and self-expandable metal stents. Clin Colorectal Cancer. 2019 Sep; 18(3): e287-93.
42. Han JP, Hong SJ, Kim SH, et al. Palliative self-expandable metal stents for acute malignant colorectal obstruction: clinical outcomes and risk factors for complications. Scand J Gastroenterol. 2014 Aug; 49(8): 967-73.
43. Kim BC, Han KS, Hong CW, et al. Clinical outcomes of palliative self-expanding metallic stents in patients with malignant colorectal obstruction. J Dig Dis. 2012 May; 13(5): 258-66.
44. Yoon JY, Jung YS, Hong SP, et al. Clinical outcomes and risk fac-
tors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc. 2011 Oct; 74(4): 858-68.

45. Martinez-Santos C, Lobato RF, Fradejas JM, et al. Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates. Dis Colon Rectum. 2002 Mar; 45(3): 401-6.

46. Ng KC, Law WL, Lee YM, et al. Self-expanding metallic stent as a bridge to surgery versus emergency resection for obstructing left-sided colorectal cancer: a case-matched study. J Gastrointest Surg. 2006 Jun; 10(6): 798-803.

47. Sebastian S, Johnston S, Geoghegan T, et al. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol. 2004 Oct; 99(10): 2051-7.

48. Lee HJ, Hong SP, Cheon JH, et al. Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. Gastrointest Endosc. 2011 Mar; 73(3): 535-42.

49. Luigiano C, Ferrara F, Fabbri C, et al. Through-the-scope large diameter self-expanding metal stent placement as a safe and effective technique for palliation of malignant colorectal obstruction: a single center experience with a long-term follow-up. Scand J Gastroenterol. 2011 May; 46(5): 591-6.

50. Ceze N, Charachon A, Locher C, et al. Safety and efficacy of palliative systemic chemotherapy combined with self-expandable metallic stents in advanced colorectal cancer: A multicenter study. Clin Res Hepatol Gastroenterol. 2016 Apr; 40(2): 230-8.

51. Fuccio L, Correale L, Arezzo A, et al. Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. Dig Liver Dis. 2014 Jun; 46(6): 561-7.

52. Karoui M, Charachon A, Delbaldo C, et al. Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. Arch Surg. 2007 Jul; 142(7): 619-23; discussion 23.

53. Lee WS, Baek JH, Kang JM, et al. The outcome after stent placement or surgery as the initial treatment for obstructive primary tumor in patients with stage IV colon cancer. Am J Surg. 2012 Jun; 203(6): 715-9.

54. Abbott S, Eglinton TW, Ma Y, et al. Predictors of outcome in palliative colonic stent placement for malignant obstruction. Brit J Surg. 2014 Jan; 101(2): 121-6.

55. Fernandez-Esparrach G, Bordas JM, Giraldes MD, et al. Severe complications limit long-term clinical success of self-expanding metal stents in patients with obstructive colorectal cancer. Am J Gastroenterol. 2010 May; 105(5): 1087-93.

56. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFIRI and bevacizumab for metastatic colorectal cancer. New Engl J Med. 2014 Oct; 371(17): 1609-18.

57. Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013 Dec; 14(13): 1278-86.

58. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016 Aug; 27(8): 1539-46.

59. Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8): 1126-32.

60. Imbulgoda A, MacLean A, Heine J, et al. Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review. Can J Surg. 2015 Jun; 58(3): 167-71.

61. Cennamo V, Fuccio L, Mutri V, et al. Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy? Clin Gastroenterol Hepatol. 2009 Nov; 7(11): 1174-6.

62. van Halsema EE, van Hooft JE, Small AJ, et al. Perforation in colorectal stenting: a meta-analysis and a search for risk factors. Gastrointest Endosc. 2014 Jun; 79(6): 970-82.

63. Park YE, Park Y, Park SJ, et al. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. Surg Endosc. 2019 Apr; 33(4): 1225-34.

64. Bong JW, Lee JL, Kim CW, et al. Risk factors and adequate management for complications of bevacizumab treatment requiring surgical intervention in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2018 Dec; 17(4): e639-45.

65. Lee YJ, Yoon JY, Park JJ, et al. Clinical outcomes and factors related to colonic perforations in patients receiving self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc. 2018 Jun; 87(6): 1548-57.

66. van Hooft JE, van Halsema EE, Vaniervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2014 Nov; 46(11): 990-1053.

67. van Hooft JE, Veld JV, Arnold D, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. 2020 May; 52(5): 389-407.

68. Pisano M, Zorccolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018 Dec; 13(1): 1-27.

69. Sultz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr; 26(12): 2013-9.

70. Wong HL, Lee B, Field K, et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer. 2016 Jun; 15(2): e9-e15.

71. Colloca GA, Venturino A, Guarneri D. Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis. Int J Clin Oncol. 2019 Mar; 24(3): 231-40.

72. Yamada T, Matsuda A, Koizumi M, et al. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019; 99(1): 39-45.